- Home
- YHGJ vs NCEL Comparison
YHGJ vs NCEL Comparison
Compare YHGJ & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YHGJ | NCEL |
|---|---|---|
| Founded | 1975 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | 11 |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 13.2M |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | YHGJ | NCEL |
|---|---|---|
| Price | $3.00 | $2.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.3K | ★ 16.8K |
| Earning Date | 04-14-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,953,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.84 | N/A |
| 52 Week Low | $0.47 | $1.89 |
| 52 Week High | $10.29 | $4.70 |
Technical Indicators
Market Signals| Indicator | YHGJ | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 44.82 |
| Support Level | $2.45 | $2.63 |
| Resistance Level | $3.03 | $3.16 |
| Average True Range (ATR) | 0.26 | 0.15 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 51.38 | 17.86 |
Price Performance
Historical ComparisonAbout YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.